Trials / Withdrawn
WithdrawnNCT02905201
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Exposed to Abiraterone Acetate (TOGETHER)
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the rate of compliance to abiraterone acetate and prednisone (AA + P) treatment in Colombian Castration-resistant metastatic prostate cancer (mCRPC) participants experiencing adequate response to treatment, in a real-world clinical setting.
Conditions
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-08-01
- Completion
- 2018-04-01
- First posted
- 2016-09-19
- Last updated
- 2025-02-03
Source: ClinicalTrials.gov record NCT02905201. Inclusion in this directory is not an endorsement.